ABOUT US
VCARE PHARMATECH
Jiangsu Vcare PharmaTech Co., Ltd.(Jiangsu Vcare), established in 2010, is a high-tech biopharmaceutical company dedicated to addressing unmet clinical needs through differentiated innovation in drug and advanced therapy development. Since our inception, we’ve experienced rapid growth and evolved into a group-style enterprise with a strong foundation in two core business segments: innovative drug R&D and comprehensive pharmaceutical industry chain services. With 15 years of experience and a forward-looking mindset, Jiangsu Vcare continues to shape the future of biopharma through technology, quality, and purpose-driven innovation.
INNOVATIVE DRUGS
Jiangsu Vcare's proprietary innovative drug R&D business adheres to a differentiated strategy addressing unmet clinical needs. Based on innovative approaches including "overcoming therapeutic resistance", "resolving drug resistance", and "enhancing target selectivity", the company has established a tiered pipeline architecture centered on Vicagrel. Currently, it possesses five Class I innovative drugs in clinical development: VC004 capsules (oral anti-tumor targeted therapy); Vicagrel capsules (oral anti-thrombotic agent); VC005 tablets (oral immunomodulatory and anti-inflammatory agent); VC005 gel (topical immunomodulatory and anti-inflammatory formulation). Additionally, multiple preclinical projects are progressing through the pipeline, with therapeutic focuses spanning cardiovascular/cerebrovascular diseases, oncology, and autoimmune/inflammatory disorders. This strategic portfolio positions the company for comprehensive coverage of global pharmaceutical markets in the future.
INNOVATION PLATFORM
Innovative Drugs - Medicine - Pharmacy - Chemistry; Covering The Entire Life Cycle Of New Drug Research And Development
NEWS
2025-10-31
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
2025-09-29
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
2025-09-24
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn